FDA Approves Lynparza for Certain Advanced Ovarian Cancer

Lynparza is indicated for patients with deleterious or suspected deleterious gBRCAm or sBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, who have complete or partial response to first-line platinum-based chemotherapy. 

Source link